HPA008736

antibody from Atlas Antibodies

Targeting: DAXX DAP6

Provider product page for HPA008736

Western blot

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [37]
Comments [0]
Validations
Western blot [2]
Immunohistochemistry [1]

Submit

Product number: HPA008736 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA008736, RRID:AB_1078625
Product name: Anti-DAXX
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human DAXX, Gene description: death-domain associated protein, Alternative Gene Names: DAP6, Validated applications: IHC, WB, Uniprot ID: Q9UER7, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.1 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

DAXX protein structure - HPA008736 shown in red.

Submitted references Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies

April-Monn S, Kirchner P, Detjen K, Bräutigam K, Trippel M, Grob T, Statzer C, Maire R, Kollàr A, Chouchane A, Kunze C, Horst D, Sadowski M, Schrader J, Marinoni I, Wiedenmann B, Perren A
npj Precision Oncology 2024;8(1)

DAXX adds a de novo H3.3K9me3 deposition pathway to the histone chaperone network

Carraro M, Hendriks I, Hammond C, Solis-Mezarino V, Völker-Albert M, Elsborg J, Weisser M, Spanos C, Montoya G, Rappsilber J, Imhof A, Nielsen M, Groth A
Molecular Cell 2023;83(7):1075-1092.e9

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

Hackeng W, Brosens L, Kim J, O'Sullivan R, Sung Y, Liu T, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink F, Heidsma C, Valk G, Vriens M, Nieveen van Dijkum E, Offerhaus G, Dreijerink K, Zeh H, Zureikat A, Hogg M, Lee K, Geller D, Marsh J, Paniccia A, Ongchin M, Pingpank J, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella K, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova M, Lawlor R, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong S, Heaphy C, Singhi A
Gut 2022;71(5):961-973

Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast

Yanai H, Ishida M, Yoshikawa K, Tsuta K, Sekimoto M, Sugie T
Oncology Letters 2022;23(4)

Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis

Bremer S, Bittner G, Elakad O, Dinter H, Gaedcke J, König A, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P, Bohnenberger H
Cancers 2022;14(12):2828

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT

de Nonneville A, Salas S, Bertucci F, Sobinoff A, Adélaïde J, Guille A, Finetti P, Noble J, Churikov D, Chaffanet M, Lavit E, Pickett H, Bouvier C, Birnbaum D, Reddel R, Géli V
EMBO Molecular Medicine 2022;14(10)

DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network

Hammond C, Bao H, Hendriks I, Carraro M, García-Nieto A, Liu Y, Reverón-Gómez N, Spanos C, Chen L, Rappsilber J, Nielsen M, Patel D, Huang H, Groth A
Molecular Cell 2021;81(12):2533-2548.e9

Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma

Davidson B, McFadden E, Holth A, Brunetti M, Flørenes V
Virchows Archiv 2020;477(6):857-864

Telomere length alterations and ATRX/DAXX loss in pituitary adenomas

Heaphy C, Bi W, Coy S, Davis C, Gallia G, Santagata S, Rodriguez F
Modern Pathology 2020;33(8):1475-1481

Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas

Hackeng W, Schelhaas W, Morsink F, Heidsma C, van Eeden S, Valk G, Vriens M, Heaphy C, Nieveen van Dijkum E, Offerhaus G, Dreijerink K, Brosens L
Endocrine Pathology 2020;31(2):108-118

Telomere alterations in neurofibromatosis type 1-associated solid tumors

Rodriguez F, Graham M, Brosnan-Cashman J, Barber J, Davis C, Vizcaino M, Palsgrove D, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood L, Pratilas C, Morris C, Belzberg A, Blakeley J, Heaphy C
Acta Neuropathologica Communications 2019;7(1)

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

Graham M, Kim J, Da J, Brosnan-Cashman J, Rizzo A, Baena Del Valle J, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner M, De Marzo A, Meeker A, Heaphy C
Molecular Cancer Research 2019;17(12):2480-2491

A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes

Jin C, Hacking S, Komforti M, Nasim M
Biomarker Insights 2019;14

Importance of Promyelocytic Leukema Protein (PML) for Kaposi’s Sarcoma-Associated Herpesvirus Lytic Replication

Hossain M, Ohsaki E, Honda T, Ueda K
Frontiers in Microbiology 2018;9

A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease

Bell W, Meeker A, Rizzo A, Rajpara S, Rosenthal I, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber J, Joshu C, Canto‐Soler M, Eberhart C, Heaphy C
Brain Pathology 2018;29(1):45-52

Alternative lengthening of telomeres, ATRX loss and H3‐K27M mutations in histologically defined pilocytic astrocytoma with anaplasia

Rodriguez F, Brosnan‐Cashman J, Allen S, Vizcaino M, Giannini C, Camelo‐Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis L, Alnajar H, Barber J, Rodríguez‐Velasco A, Orr B, Heaphy C
Brain Pathology 2018;29(1):126-140

Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T
Disease Markers 2018;2018

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner

Ouellette M, Brosnan-Cashman J, Yuan M, Graham M, Rizzo A, Myers K, Davis C, Zhang R, Esopi D, Raabe E, Eberhart C, Heaphy C, Meeker A
PLOS ONE 2018;13(9):e0204159

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors

Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y
Oncotarget 2017;8(30):49796-49806

Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero J, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C
Oncotarget 2017;8(25):41044-41063

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival

Kim J, Brosnan-Cashman J, An S, Kim S, Song K, Kim M, Kim M, Hwang D, Meeker A, Yu E, Kim S, Hruban R, Heaphy C, Hong S
Clinical Cancer Research 2017;23(6):1598-1606

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors

Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, Tsung A, Marsh J, Lee K, Hogg M, Bahary N, Brand R, McGrath K, Slivka A, Cressman K, Fuhrer K, O'Sullivan R
Clinical Cancer Research 2017;23(2):600-609

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors

VandenBussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, Hruban R, Heaphy C
Cancer Cytopathology 2017;125(7):544-551

Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis

Lin C, Wang L, Wang S, Chang Y, Wu Y, Chen H, Hsiao T, Lai W, Lu H, Chang Y, Yang S, Lin M, Chen C, Hong T, Yang P
Nature Communications 2016;7(1)

TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes

Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira R, Gonçalves A, Pestana A, Reis M, Mesquita B, Pinto V, Lyra J, Cipriano M, Ferreira M, Lopes J, Sobrinho-Simões M, Soares P
Scientific Reports 2016;6(1)

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12

Morton C, Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P
PLOS Genetics 2016;12(2):e1005850

ATRX represses alternative lengthening of telomeres

Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, Reddel R
Oncotarget 2015;6(18):16543-16558

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas

Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, Cho N, Greenberg R, Else T, Montone K, LiVolsi V, Fraker D, Daber R, Cohen D, Nathanson K
Nature Communications 2015;6(1)

Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours

Pipinikas C, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris T, Salomoni P, Luong T, Davidson B, Beck S, Thirlwell C
Endocrine-Related Cancer 2015;22(3):L13-L18

TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast

Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British Journal of Cancer 2015;113(8):1244-1248

Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma

Slatter T, Hsia H, Samaranayaka A, Sykes P, Clow W, Devenish C, Sutton T, Royds J, PC P, Cheung A, Hung N
The Journal of Pathology: Clinical Research 2015;1(2):95-105

TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast

Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British Journal of Cancer 2015 September;113(8):1244-1248

ATRX represses alternative lengthening of telomeres

Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, Reddel R
Oncotarget 2015 June;6(18):16543-16558

Sp100 Provides Intrinsic Immunity against Human Papillomavirus Infection

Stepp W, Meyers J, McBride A, Imperiale M
mBio 2013;4(6)

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K, Sturm D, Fontebasso A, Quang D, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel J, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann M, Scheurlen W, Pekrun A, Frühwald M, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski P, Dong Z, Siegel P, Kulozik A, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins V, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister S, Jabado N
Nature 2012;482(7384):226-231

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors

de Wilde R, Heaphy C, Maitra A, Meeker A, Edil B, Wolfgang C, Ellison T, Schulick R, Molenaar I, Valk G, Vriens M, Borel Rinkes I, Offerhaus G, Hruban R, Matsukuma K
Modern Pathology 2012;25(7):1033-1039

Altered Telomeres in Tumors with ATRX and DAXX Mutations

Heaphy C, de Wilde R, Jiao Y, Klein A, Edil B, Shi C, Bettegowda C, Rodriguez F, Eberhart C, Hebbar S, Offerhaus G, McLendon R, Rasheed B, He Y, Yan H, Bigner D, Oba-Shinjo S, Marie S, Riggins G, Kinzler K, Vogelstein B, Hruban R, Maitra A, Papadopoulos N, Meeker A
Science 2011;333(6041):425-425

No comments: Submit comment

Enhanced validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Genetic validation
Main image
Experimental details: Western blot analysis in HEK293 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-DAXX antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
Sample type: Human
Protocol: Protocol

Enhanced validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Recombinant expression validation
Main image
Experimental details: Western blot analysis in control (vector only transfected HEK293T lysate) and DAXX over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY427987).
Sample type: Human
Protocol: Protocol

Supportive validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Orthogonal validation
Main image
Experimental details: Immunohistochemistry analysis in human testis and skeletal muscle tissues using HPA008736 antibody. Corresponding DAXX RNA-seq data are presented for the same tissues.
Sample type: Human
Protocol: Protocol
Orthogonal method: Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

: Show more